thrombocythemia

MPN Research Foundation President Barbara Van Husen explains, Myelofibrosis is the deadliest of the MPNs myeloproliferative neoplasms, and patients of both polycythemia vera and essential thrombocythemia have the potential to convert to myelofibrosis.

Forbes.com: News Alex Knapp 2012

Phase 2 clinical trials are open in multiple myeloma and essential thrombocythemia.

Geron Announces Publication Demonstrating Activity of Imetelstat Against Cancer Stem Cells From Pediatric Neural Tumors - Yahoo! Finance 2011

Hematology Annual Meeting in December involving patients with myelofibrosis, patients with advanced polycythemia vera and essential thrombocythemia refractory to hydroxyurea and patients with relapsed or refractory hematological malignancies.

THE MEDICAL NEWS Editors 2010

"Key objectives for 2010 include completing our US Phase III registration trial for INCB18424 in myelofibrosis, determining product registration requirements for INCB18424 as a treatment for polycythemia vera and possibly essential thrombocythemia, and reporting Phase II results for INCB28050 for rheumatoid arthritis which we expect will support moving forward into a larger Phase IIb trial with our partner, Eli Lilly."

THE MEDICAL NEWS Editors 2010

CYT387 in a Phase I dose-escalation study in patients with high- or intermediate-risk primary myelofibrosis (PMF) and post-PV or post-essential thrombocythemia (ET) myelofibrosis.

Ym Biosciences Reports Significant Response Rates in Anemia, Splenomegaly, and Constitutional Symptoms From the Phase I/II Trial of its Jak1/Jak2 Inhibitor, Cyt387, in Myelofibrosis - Yahoo! Finance 2010

"Key objectives for 2010 include completing our US Phase III registration trial for INCB18424 in myelofibrosis, determining product registration requirements for INCB18424 as a treatment for polycythemia vera and possibly essential thrombocythemia, and reporting Phase II results for INCB28050 for rheumatoid arthritis which we expect will support moving forward into a larger Phase IIb trial with our partner, Eli Lilly."

THE MEDICAL NEWS Editors 2010

Hematology Annual Meeting in December involving patients with myelofibrosis, patients with advanced polycythemia vera and essential thrombocythemia refractory to hydroxyurea and patients with relapsed or refractory hematological malignancies.

THE MEDICAL NEWS Editors 2010

(PV) who are not responding to hydroxyurea, and essential thrombocythemia (ET).

INCY's INC424 Meets Goal - Yahoo! Finance 2010

The three main MPNs are polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF).

unknown title 2009

The three main MPNs are polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF).

The Earth Times Online Newspaper 2009